Subsidies & Funding

We empower medical innovation

Project Management

We manage your EU Horizon 2020 project

Business Strategy

We support successful commercialisation

Funding database

EU & non EU subsidies


Upcoming call: New concepts in patient stratification

April 26 2016

Within the upcoming round of the Societal Challenges (SC1) call in the 2016-2017 Horizon2020 work programme, ttopstart has selected the 4 major topics with a pre-proposal stage in October of this year to help you prepare for this first stage deadline. Today we discuss the first: ‘PM-02-New concepts in patient stratification’.

Many current treatments, drugs or diagnostics are only effective in a subset of patients. This poses an increasing challenge for clinicians to make a weighted knowledge-based decision to match a patient with a treatment. This complicates tailored interventions to individual patients or patient groups with a shared molecular phenotype. An in-depth knowledge and definition on the varieties of the specific pathological processes helps to stratify patients into disease sub-groups, facilitating treatment decision making and resulting in greater treatment success.


The topic calls for novel concepts for disease mechanisms based patient stratification to address the needs for stratified or personalised therapeutic interventions in highly complex diseases. Integration of multidimensional and longitudinal data are key, including the omics-promise of pharmacogenomics, systems biomedicine approaches, network analysis and computational modelling. Validation should take place in pre-clinical and clinical studies.


The commission expects new models for patient stratification to inform clinical decision making by accelerating the translation of biomedical and clinical research results to medical use. The new models should increase the cost-effectiveness in comparison to the current practice. The novelty should yield increased research and innovation opportunities for the SME driven industry.

A proposal for this topic should describe a new concept with a basis already established in the lab, which will be studied in a clinical setting while taking into account a complete pathway analysis and/or a systems medicine approach. Examples are diseases for which a treatment is not always curative in a percentage of patients, who can currently not be identified prior to the start of the treatment. A typical consortium should include both fundamental and clinical researchers, computational modellers, and the capacity to integrate different types of data. The participation of a partner to commercialise the project outcomes greatly enhances the impact.

From our elaborate expertise in these health related calls and previous successful proposals we have made a solid interpretation of these new topics which allows us to provide you with optimal support in the preparation of your proposal. If the description above relates to your research or activities, we invite you to contact us to further discuss whether there is a good match with this call-topic, and how we can help you.

Stage1: October 4 2016
​Stage2: April 11 2017

Share this